Biofrontera Inc. reported financial results for the second quarter and first half of 2026, ending June 30. Second-quarter net product revenue rose 32.9% to $12.0 million from $9.0 million in the prior-year period, driven by unit volume growth and a price increase. Gross margin improved to 80% from 71%, reflecting a lower cost structure following a strategic transaction with Biofrontera AG. The company reported a net loss of $0.6 million, or $(0.05) per share, compared to a $5.3 million loss in the prior year. Adjusted EBITDA improved significantly to $(0.2) million from $(5.1) million. For the first half of 2026, revenue increased 25.4% to $22.1 million, with a net loss of $5.4 million and adjusted EBITDA of $(3.7) million. Cash used in operating activities for the six-month period was $1.7 million. The company is a biopharmaceutical firm specializing in photodynamic therapy products for dermatological conditions.